(Q34481499)

2 August 2017

1 reference

title

Novel approaches in the treatment of lupus nephritis. (English)

1 reference

2 August 2017

Illei GG

1

1 reference

PubMed ID

11772239

2 August 2017

Czirják L

series ordinal

2

1 reference

PubMed ID

11772239

2 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

6

1 reference

2 August 2017

1117-1130

1 reference

Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells.

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Immune ablation and stem-cell therapy in autoimmune disease. Clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Clinical and toxicological aspects of the antineoplastic drug cladribine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Intravenous immunoglobulin treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Features of systemic lupus erythematosus in Dnase1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Treatment of membranous lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

New therapies for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Mechanism of action of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.6.1117

10.1517/13543784.10.6.1117

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11772239